Saturday, February 1, 2025
HomeIndustriesBiotechnology

Biotechnology

Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

Antengene Corporation Limited, a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life-threatening...

PharmAbcine Announces First Patient Enrolled and Dosed in the Phase II Clinical Trial for the Treatment of mTNBC

PharmAbcine Inc., a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced it has dosed the first patient in its...

EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH

EOFlow Co., Ltd., a provider of wearable drug delivery solutions, has announced that its wholly owned US subsidiary, EOFlow Inc. has signed an agreement...

Kolon Tissuegene Resumes TG-C Phase III Studies in the US

Kolon TissueGene, Inc., a leader in advanced cell and gene therapies, announced that it has resumed patient dosing in its U.S. Phase III study...

Soin Therapeutics Completes Formulation Development of Novel Low Dose Naltrexone Tablet to Treat Complex Regional Pain Syndrome

Soin Therapeutics, a biotechnology company based in Dayton, OH, has completed the formulation development work of their novel, proprietary low dose naltrexone pill to...
0FansLike
0FollowersFollow
spot_img

Hot Topics